D
Daniel Aletaha
Researcher at Medical University of Vienna
Publications - 398
Citations - 51111
Daniel Aletaha is an academic researcher from Medical University of Vienna. The author has contributed to research in topics: Rheumatoid arthritis & Medicine. The author has an hindex of 74, co-authored 298 publications receiving 43215 citations. Previous affiliations of Daniel Aletaha include National Institutes of Health & University of Vienna.
Papers
More filters
Journal ArticleDOI
From the item to the outcome: the promising prospects of PROMIS
TL;DR: A new approach to the assessment of physical function uses computerised adaptive testing, by which precision and reliability of the measurement can be achieved for most patients, while even requiring less time for the assessment.
Journal ArticleDOI
Reliability of patient-reported outcomes in rheumatoid arthritis patients: an observational prospective study
TL;DR: The relatively high SDDs, even for patients in the lowest tertiles of their PROs, indicate potential issues for assessment of the presence of remission, and is dependent on the tested time interval and the baseline levels.
Journal ArticleDOI
How Do Gastrointestinal or Liver Comorbidities Influence the Choice of Pain Treatment in Inflammatory Arthritis? A Cochrane Systematic Review
Helga Radner,Sofia Ramiro,Désirée van der Heijde,Robert Landewé,Rachelle Buchbinder,Daniel Aletaha +5 more
TL;DR: Very little evidence regarding safety and efficacy of pain treatment in patients with IA and GI or hepatic comorbidities was found and NSAID should be used cautiously since there is evidence that these patients are at a higher risk of developing adverse events.
Journal ArticleDOI
Synovitis in rheumatoid arthritis detected by grey scale ultrasound predicts the development of erosions over the next three years.
Burkhard Möller,Daniel Aletaha,Michael Andor,Andrew Atkinson,Bérengère Aubry-Rozier,Laure Brulhart,Diana Dan,Axel Finckh,Véronique Grobéty,Peter Mandl,Raphael Micheroli,Michael John Nissen,Alexander M Nydegger,Almut Scherer,Giorgio Tamborrini,Hans-Rudolf Ziswiler,Pascal Zufferey +16 more
TL;DR: Higher levels of grey scale US appears to be an essential component of synovitis assessment and an independent predictor of joint damage progression in patients on biological DMARDs.
Journal ArticleDOI
Step-up combination versus switching of non-biological disease-modifying antirheumatic drugs in rheumatoid arthritis: results from a retrospective observational study.
TL;DR: The present data indicate that in situations of ineffective DMARD treatments, step-up combination therapy using traditional DMARDs, such as MTX, SSZ or LEF, bears no clear clinical advantage over switching to the new DMARD.